Definition & Core Concept

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous, biologically active respiratory condition defined by chronic respiratory symptoms including dyspnea, chronic cough, and copious sputum production. These symptoms arise secondary to profound airway abnormalities (chronic bronchitis and bronchiolitis) and irreversible alveolar destruction (emphysema) that collectively cause persistent airflow obstruction.

The 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report introduces a monumental conceptual paradigm shift by reclassifying COPD as a dynamic disease defined by its biological ‘disease activity,’ moving far beyond historical models that viewed the disease solely through the lens of static spirometric airflow limitation. Disease activity refers to the underlying, highly active inflammatory processes that, if unmitigated, drive accelerated lung function decline and permanent organ damage.

Pathophysiology

COPD pathophysiology involves three interconnected mechanisms:

1. Chronic Airway Inflammation: Chronic exposure to noxious particles triggers an inflammatory response in the airways and lung parenchyma. This leads to mucosal edema, goblet cell hyperplasia, and smooth muscle hypertrophy.
2. Parenchymal Destruction (Emphysema): Proteolytic enzymes (primarily neutrophil elastase and matrix metalloproteinases) degrade alveolar walls, leading to loss of elastic recoil and airway collapse during expiration. This results in air trapping and hyperinflation.
3. Mucociliary Dysfunction: Impaired ciliary function leads to mucus accumulation, providing a nidus for bacterial colonization and infection.

Alpha-1 antitrypsin deficiency (AATD) should be suspected in patients with early-onset COPD, predominantly basilar emphysema, or a family history of liver disease.

Clinical Presentation

Cardinal Symptoms:

• Dyspnea: Progressive, persistent, worse with exertion, often described as ‘increased effort to breathe’
• Chronic cough: Initially intermittent, becomes daily and persistent
• Sputum production: Chronic, often purulent during exacerbations
• Wheeze: Expiratory, indicates airway narrowing
• Chest tightness: Variable, often worse in the morning

Physical Examination:

• Barrel chest: Increased anteroposterior diameter
• Hyperresonance on percussion
• Wheezing or crackles on auscultation
• Prolonged expiratory phase
• Pursed-lip breathing
• Accessory muscle use (sternocleidomastoid, intercostal muscles)
• Digital clubbing (suggests underlying lung cancer or bronchiectasis)
• Signs of cor pulmonale: JVD, peripheral edema, hepatomegaly

Diagnostic Workup

Spirometry (Mandatory):

• FEV1/FVC ratio <0.70 (post-bronchodilator) confirms persistent airflow obstruction
• Lower limit of normal (LLN) recommended for optimal diagnostic precision
• Assess severity based on FEV1 % predicted

Additional Studies:

• Chest X-ray: Hyperinflation, flattened diaphragms, rapid tapering of vascular shadows
• CT Chest: Evaluate for emphysema distribution, bronchiectasis, lung nodules
• Arterial blood gas (ABG): Assess for hypoxemia and hypercapnia in advanced disease
• Blood eosinophil count (BEC): Guides ICS use (BEC ≥300 cells/µL = consider ICS)
• Alpha-1 antitrypsin level: Screen in early-onset COPD or predominant basilar emphysema
• BNP: Distinguish COPD from heart failure when dyspnea is unclear

Case-Finding Questionnaires:

• COPD Population Screener (COPD-PS)
• Lung Function Questionnaire (LFQ)
• COPD Diagnostic Questionnaire (CDQ)
• PUMA
• Capture

Complications & Prognosis

Major Complications:

• Exacerbations: Acute worsening requiring antibiotics, steroids, or hospitalization
• Respiratory failure: Type I (hypoxemic) or Type II (hypercapnic)
• Cor pulmonale: Right ventricular failure due to pulmonary hypertension
• Secondary polycythemia: Chronic hypoxemia → increased erythropoietin
• Pulmonary hypertension
• Lung cancer: Increased risk in COPD patients
• Osteoporosis (especially with chronic corticosteroid use)
• Depression and anxiety

Prognosis:

• BODE index predicts mortality (BMI, airflow Obstruction, Dyspnea, Exercise capacity)
• FEV1 is the strongest predictor of mortality
• Exacerbations accelerate disease progression
• 5-year mortality ~20-30% for moderate COPD, >50% for severe

Admission vs. ICU Criteria

Indications for Admission:

• Acute exacerbation with significant dyspnea (mMRC ≥3)
• Inability to maintain oral intake
• Altered mental status
• New or worsening hypoxemia (PaO2 45 mmHg)
• Significant comorbidities (CHF, pneumonia, arrhythmias)

ICU Admission Criteria:

• Respiratory failure requiring non-invasive or invasive mechanical ventilation
• Hemodynamic instability
• Altered consciousness or confusion
• Persistent hypoxemia despite high-flow oxygen
• Need for continuous monitoring
• Arrhythmias or acute coronary syndrome

Discharge & Outpatient Follow-up

• Follow-up: Primary care within 7 days, pulmonary clinic within 30 days
• Pulmonary rehabilitation: Referral strongly recommended
• Smoking cessation: Counseling and pharmacotherapy (varenicline, nicotine replacement)
• Vaccination update: Ensure influenza, pneumococcal, COVID-19, RSV (if ≥60) up-to-date
• Inhaler technique: Review at every visit
• Action plan: Provide written exacerbation action plan
• Sleep study: Consider if suspected OSA

Literature & Guidelines

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report. Published November 2025.

Available at: https://goldcopd.org/

Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.

Rabe KF, Watz H. ‘Global Initiative for Chronic Obstructive Lung Disease: the 2026 GOLD report—a paradigm shift in disease definition, assessment, and management.’ Lancet. 2025; In Press.